Hypertrophic cardiomyopathy: a heart in need of an energy bar?

Mitochondria: hubs of cellular signaling, energetics and redox balance. A rich, vibrant, and diverse landscape of mitochondrial research. Front Physiol (2015) 0.77

Downregulation of GSTK1 Is a Common Mechanism Underlying Hypertrophic Cardiomyopathy. Front Pharmacol (2016) 0.77

Sex-related differences in the associations between plasma free fatty acid levels and clinical features in patients with hypertrophic cardiomyopathy. Biol Sex Differ (2016) 0.75

Modulating Beta-Cardiac Myosin Function at the Molecular and Tissue Levels. Front Physiol (2017) 0.75

Cardiac excitation-contraction coupling. Nature (2002) 18.48

Mitochondria, oxidants, and aging. Cell (2005) 16.11

Hypertrophic cardiomyopathy: a systematic review. JAMA (2002) 9.15

Asymmetrical hypertrophy of the heart in young adults. Br Heart J (1958) 7.38

Reactive oxygen species (ROS)-induced ROS release: a new phenomenon accompanying induction of the mitochondrial permeability transition in cardiac myocytes. J Exp Med (2000) 5.90

A molecular basis for familial hypertrophic cardiomyopathy: a beta cardiac myosin heavy chain gene missense mutation. Cell (1990) 5.77

Hypertrophic cardiomyopathy. Lancet (2012) 5.44

The genetic basis for cardiomyopathy: from mutation identification to mechanistic paradigms. Cell (2001) 5.35

Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. N Engl J Med (2003) 5.17

Alpha-tropomyosin and cardiac troponin T mutations cause familial hypertrophic cardiomyopathy: a disease of the sarcomere. Cell (1994) 4.47

Aconitase and mitochondrial iron-sulphur protein deficiency in Friedreich ataxia. Nat Genet (1997) 4.26

Synchronized whole cell oscillations in mitochondrial metabolism triggered by a local release of reactive oxygen species in cardiac myocytes. J Biol Chem (2003) 3.93

Functional obstruction of the left ventricle; acquired aortic subvalvar stenosis. Guys Hosp Rep (1957) 3.93

Mitochondrial ROS-induced ROS release: an update and review. Biochim Biophys Acta (2006) 3.57

2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Developed in collaboration with the American Association for Thoracic Surgery, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol (2011) 3.57

HYPERTROPHIC OBSTRUCTIVE CARDIOMYOPATHY. Br Heart J (1964) 3.56

Myocardial fibrosis as an early manifestation of hypertrophic cardiomyopathy. N Engl J Med (2010) 3.42

Angiotensin II blockade reverses myocardial fibrosis in a transgenic mouse model of human hypertrophic cardiomyopathy. Circulation (2001) 3.21

The mitochondrial origin of postischemic arrhythmias. J Clin Invest (2005) 3.08

Elevated cytosolic Na+ decreases mitochondrial Ca2+ uptake during excitation-contraction coupling and impairs energetic adaptation in cardiac myocytes. Circ Res (2006) 3.03

The molecular genetic basis for hypertrophic cardiomyopathy. J Mol Cell Cardiol (2001) 2.83

Late sodium current inhibition reverses electromechanical dysfunction in human hypertrophic cardiomyopathy. Circulation (2012) 2.78

Differential activation of signal transduction pathways in human hearts with hypertrophy versus advanced heart failure. Circulation (2001) 2.76

Mapping a gene for familial hypertrophic cardiomyopathy to chromosome 14q1. N Engl J Med (1989) 2.70

Cardiac fibrosis in mice with hypertrophic cardiomyopathy is mediated by non-myocyte proliferation and requires Tgf-β. J Clin Invest (2010) 2.64

Mutations in the gamma(2) subunit of AMP-activated protein kinase cause familial hypertrophic cardiomyopathy: evidence for the central role of energy compromise in disease pathogenesis. Hum Mol Genet (2001) 2.56

Ca(2+) activation of heart mitochondrial oxidative phosphorylation: role of the F(0)/F(1)-ATPase. Am J Physiol Cell Physiol (2000) 2.45

Hypertrophic cardiomyopathy. Lancet (2004) 2.41

Prevention of cardiac hypertrophy in mice by calcineurin inhibition. Science (1998) 2.39

Energy metabolism in heart failure and remodelling. Cardiovasc Res (2008) 2.37

Abnormal calcium handling properties underlie familial hypertrophic cardiomyopathy pathology in patient-specific induced pluripotent stem cells. Cell Stem Cell (2013) 2.33

Oxidative stress and redox signalling in cardiac hypertrophy and heart failure. Heart (2006) 2.28

The L-type calcium channel inhibitor diltiazem prevents cardiomyopathy in a mouse model. J Clin Invest (2002) 2.26

Inherited cardiomyopathies. N Engl J Med (2011) 2.25

Redox modification of ryanodine receptors contributes to sarcoplasmic reticulum Ca2+ leak in chronic heart failure. Circ Res (2008) 2.24

Risk of sudden death and outcome in patients with hypertrophic cardiomyopathy with benign presentation and without risk factors. Am J Cardiol (2014) 2.07

Cardiac system bioenergetics: metabolic basis of the Frank-Starling law. J Physiol (2006) 2.06

31P NMR spectroscopy detects metabolic abnormalities in asymptomatic patients with hypertrophic cardiomyopathy. Circulation (1998) 2.06

The mechanism of the intraventricular pressure gradient in idiopathic hypertrophic subaortic stenosis. Circulation (1966) 1.97

Metabolic modulator perhexiline corrects energy deficiency and improves exercise capacity in symptomatic hypertrophic cardiomyopathy. Circulation (2010) 1.96

Cardiac troponin T mutations result in allele-specific phenotypes in a mouse model for hypertrophic cardiomyopathy. J Clin Invest (1999) 1.95

Diastolic dysfunction and altered energetics in the alphaMHC403/+ mouse model of familial hypertrophic cardiomyopathy. J Clin Invest (1998) 1.94

Mitochondrial ion channels: gatekeepers of life and death. Physiology (Bethesda) (2005) 1.94

The pathogenesis of familial hypertrophic cardiomyopathy: early and evolving effects from an alpha-cardiac myosin heavy chain missense mutation. Nat Med (1999) 1.93

The role of Ca(2+) signaling in the coordination of mitochondrial ATP production with cardiac work. Biochim Biophys Acta (2009) 1.92

Hypertrophic cardiomyopathy due to sarcomeric gene mutations is characterized by impaired energy metabolism irrespective of the degree of hypertrophy. J Am Coll Cardiol (2003) 1.84

Dilated and hypertrophic cardiomyopathy mutations in troponin and alpha-tropomyosin have opposing effects on the calcium affinity of cardiac thin filaments. Circ Res (2007) 1.80

Survival after alcohol septal ablation for obstructive hypertrophic cardiomyopathy. Circulation (2012) 1.77

Excitation-contraction coupling and mitochondrial energetics. Basic Res Cardiol (2007) 1.74

A computational model integrating electrophysiology, contraction, and mitochondrial bioenergetics in the ventricular myocyte. Biophys J (2006) 1.69

Mitochondrial criticality: a new concept at the turning point of life or death. Biochim Biophys Acta (2005) 1.68

Hypertrophic cardiomyopathy:a paradigm for myocardial energy depletion. Trends Genet (2003) 1.62

Elevated cytosolic Na+ increases mitochondrial formation of reactive oxygen species in failing cardiac myocytes. Circulation (2010) 1.61

Enhancing mitochondrial Ca2+ uptake in myocytes from failing hearts restores energy supply and demand matching. Circ Res (2008) 1.60

A disease locus for familial hypertrophic cardiomyopathy maps to chromosome 1q3. Nat Genet (1993) 1.57

Decreased energetics in murine hearts bearing the R92Q mutation in cardiac troponin T. J Clin Invest (2003) 1.55

Regional myocardial blood flow and metabolism at rest in mildly symptomatic patients with hypertrophic cardiomyopathy. J Am Coll Cardiol (1989) 1.51

[Na+]i handling in the failing human heart. Cardiovasc Res (2003) 1.51

Modifier genes for hypertrophic cardiomyopathy. Curr Opin Cardiol (2002) 1.47

Atorvastatin and cardiac hypertrophy and function in hypertrophic cardiomyopathy: a pilot study. Eur J Clin Invest (2010) 1.47

Cardiac length dependence of force and force redevelopment kinetics with altered cross-bridge cycling. Biophys J (2004) 1.44

Mitochondria as a source of reactive oxygen and nitrogen species: from molecular mechanisms to human health. Antioxid Redox Signal (2013) 1.43

Hypertrophic cardiomyopathy: the genetic determinants of clinical disease expression. Nat Clin Pract Cardiovasc Med (2008) 1.43

Familial hypertrophic cardiomyopathy is a genetically heterogeneous disease. J Clin Invest (1990) 1.42

Thioredoxin reductase-2 is essential for keeping low levels of H(2)O(2) emission from isolated heart mitochondria. J Biol Chem (2011) 1.35

Prevention of cardiac hypertrophy by atorvastatin in a transgenic rabbit model of human hypertrophic cardiomyopathy. Circ Res (2005) 1.34

Changes in the chemical and dynamic properties of cardiac troponin T cause discrete cardiomyopathies in transgenic mice. Proc Natl Acad Sci U S A (2005) 1.32

Cardiomyopathy-linked myosin regulatory light chain mutations disrupt myosin strain-dependent biochemistry. Proc Natl Acad Sci U S A (2010) 1.31

Resolution of established cardiac hypertrophy and fibrosis and prevention of systolic dysfunction in a transgenic rabbit model of human cardiomyopathy through thiol-sensitive mechanisms. Circulation (2009) 1.30

Role of mitochondrial calcium transport in the control of substrate oxidation. Mol Cell Biochem (1998) 1.29

Altered crossbridge kinetics in the alphaMHC403/+ mouse model of familial hypertrophic cardiomyopathy. Circ Res (1999) 1.28

Disease pathways and novel therapeutic targets in hypertrophic cardiomyopathy. Circ Res (2011) 1.28

F110I and R278C troponin T mutations that cause familial hypertrophic cardiomyopathy affect muscle contraction in transgenic mice and reconstituted human cardiac fibers. J Biol Chem (2005) 1.28

Antifibrotic effects of antioxidant N-acetylcysteine in a mouse model of human hypertrophic cardiomyopathy mutation. J Am Coll Cardiol (2006) 1.25

Familial hypertrophic cardiomyopathy-linked alterations in Ca2+ binding of human cardiac myosin regulatory light chain affect cardiac muscle contraction. J Biol Chem (2003) 1.25

Human stem cells for modeling heart disease and for drug discovery. Sci Transl Med (2014) 1.24

Regulatory light chain mutations associated with cardiomyopathy affect myosin mechanics and kinetics. J Mol Cell Cardiol (2008) 1.23

Temporal and mutation-specific alterations in Ca2+ homeostasis differentially determine the progression of cTnT-related cardiomyopathies in murine models. Am J Physiol Heart Circ Physiol (2009) 1.21

Modification of myocardial substrate use as a therapy for heart failure. Nat Clin Pract Cardiovasc Med (2006) 1.19

Management of hypertrophic cardiomyopathy. BMJ (2006) 1.18

Research priorities in hypertrophic cardiomyopathy: report of a Working Group of the National Heart, Lung, and Blood Institute. Circulation (2010) 1.18

Clinical profile of stroke in 900 patients with hypertrophic cardiomyopathy. J Am Coll Cardiol (2002) 1.18

Metabolomics: ready for the prime time? Circ Cardiovasc Genet (2008) 1.15

Neurons and cardiomyocytes derived from induced pluripotent stem cells as a model for mitochondrial defects in Friedreich's ataxia. Dis Model Mech (2012) 1.13

Modeling cardiac action potential shortening driven by oxidative stress-induced mitochondrial oscillations in guinea pig cardiomyocytes. Biophys J (2009) 1.13

Cardiac output response and peripheral oxygen extraction during exercise among symptomatic hypertrophic cardiomyopathy patients with and without left ventricular outflow tract obstruction. Heart (2014) 1.12

R-92L and R-92W mutations in cardiac troponin T lead to distinct energetic phenotypes in intact mouse hearts. Biophys J (2007) 1.08

Pharmacological treatment options for hypertrophic cardiomyopathy: high time for evidence. Eur Heart J (2012) 1.08

The role of mitochondrial Ca2+ transport and matrix Ca2+ in signal transduction in mammalian tissues. Biochim Biophys Acta (1990) 1.07

Point mutations in mitochondrial DNA in patients with hypertrophic cardiomyopathy. Am Heart J (1992) 1.06

Myocardial metabolic changes in hypertrophic cardiomyopathy. J Nucl Med (1996) 1.04

Integrating mitochondrial energetics, redox and ROS metabolic networks: a two-compartment model. Biophys J (2013) 1.04

Relationship between oxidative stress and systolic dysfunction in patients with hypertrophic cardiomyopathy. J Card Fail (2005) 1.01

Molecular mechanisms of cardiac myofilament activation: modulation by pH and a troponin T mutant R92Q. Basic Res Cardiol (2002) 0.98

Inhibiting mitochondrial Na+/Ca2+ exchange prevents sudden death in a Guinea pig model of heart failure. Circ Res (2014) 0.98

Myocardial perfusion, oxidative metabolism, and free fatty acid uptake in patients with hypertrophic cardiomyopathy attributable to the Asp175Asn mutation in the alpha-tropomyosin gene: a positron emission tomography study. J Nucl Cardiol (2007) 0.95

Redox-optimized ROS balance and the relationship between mitochondrial respiration and ROS. Biochim Biophys Acta (2013) 0.94

Genetic inhibition of Na+-Ca2+ exchanger current disables fight or flight sinoatrial node activity without affecting resting heart rate. Circ Res (2012) 0.93

Altered cardiac excitation-contraction coupling in mutant mice with familial hypertrophic cardiomyopathy. J Clin Invest (1999) 0.93

Mitochondrial dysfunction and oxidative damage to sarcomeric proteins. Curr Hypertens Rep (2010) 0.93